scispace - formally typeset
S

S Gillis

Researcher at Amgen

Publications -  25
Citations -  2981

S Gillis is an academic researcher from Amgen. The author has contributed to research in topics: Interleukin 2 & Histamine. The author has an hindex of 19, co-authored 25 publications receiving 2956 citations. Previous affiliations of S Gillis include Johns Hopkins University.

Papers
More filters
Journal ArticleDOI

Recombinant Granulocyte-Macrophage Colony-Stimulating Factor after Autologous Bone Marrow Transplantation for Lymphoid Cancer

TL;DR: The patients given rhGM-CSF had a recovery of the neutrophil count to 500×106 per liter 7 days earlier than the patients who received placebo, suggesting that recombinant human granulocytemacrophage colony-stimulating factor may accelerate neutrophIL recovery and thereby reduce complications in patients after autologous bone marrow transplantation.
Journal Article

The human recombinant c-kit receptor ligand, rhSCF, induces mediator release from human cutaneous mast cells and enhances IgE-dependent mediator release from both skin mast cells and peripheral blood basophils.

TL;DR: Study of the effect of the human recombinant c-kit receptor ligand stem cell factor (rhSCF) on the release of inflammatory mediators from human skin mast cells and peripheral blood basophils and compared its activity to that of rhIL-3 found it to be less effective in potentiating IgE-mediated LTC4 release.
Journal ArticleDOI

Development of human mast cells from umbilical cord blood cells by recombinant human and murine c-kit ligand.

TL;DR: It was found that mast cells developed by c-kit ligand were immature even after culture for 14 weeks, and could be sensitized with human IgE for anti-IgE-induced release of histamine, prostaglandin D2, and leukotriene C4.
Journal Article

In vivo interleukin 2 administration augments the generation of alloreactive cytolytic T lymphocytes and resident natural killer cells

TL;DR: In vivo administration of highly purified IL 2, either in concert, with or 2 days after, tumor administration resulted in an augmented CTL response as compared to effector cells harvested from untreated, alloimmunized control animals.